MAB1794
Anti-Human B cells (CD19) Antibody, clone FMC63
clone FMC63, Chemicon®, from mouse
Synonim(y):
B-lymphocyte Surface Antigen B4
Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych
About This Item
Kod UNSPSC:
12352203
eCl@ss:
32160702
NACRES:
NA.43
Polecane produkty
pochodzenie biologiczne
mouse
Poziom jakości
forma przeciwciała
purified antibody
rodzaj przeciwciała
primary antibodies
klon
FMC63, monoclonal
reaktywność gatunkowa
human
producent / nazwa handlowa
Chemicon®
metody
flow cytometry: suitable
immunofluorescence: suitable
izotyp
IgG2a
numer dostępu NCBI
numer dostępu UniProt
Warunki transportu
wet ice
docelowa modyfikacja potranslacyjna
unmodified
informacje o genach
human ... CD19(930)
Powiązane kategorie
Opis ogólny
BIOCHEMISTRY:
p I = 7.0
p I = 7.0
Specyficzność
This specificity of this antibody is equivalent to that of CD19 monoclonal antibodies (Zola et al., 1988, 1989), based on comparative studies, antigen recognition and positive reaction with a CD19 transfected cell line. It detects a 96 kD single chain glycoprotein on the surface of human B lineage cells, including pre-B cells. B cells can be detected in peripheral blood and tissues. The antibody reacts with most B cell malignancies including chronic lymphocytic leukemia and most lymphomas, but not multiple myeloma.
Cell reactivity:
Normal:Stains all B lymphocytes in peripheral blood and spleen. Negative on granulocytes, monocytes, platelets, erythrocytes and T lymphocytes.
Clinical:
B cell chronic lymphocytic leukemia (B-CLL) +
Pro lymphocytic leukemia (PLL) +
Hairy cell leukemia (HCL) +
Common acute lymphoblastic leukemia (CALL) +
Pre-B acute lymphoblastic leukemia (pre-B-ALL) +
NULL-acute lymphoblastic leukemia (NULL-ALL) +
T common lymphocytic leukemia (T-CLL) -
Cell reactivity:
Normal:Stains all B lymphocytes in peripheral blood and spleen. Negative on granulocytes, monocytes, platelets, erythrocytes and T lymphocytes.
Clinical:
B cell chronic lymphocytic leukemia (B-CLL) +
Pro lymphocytic leukemia (PLL) +
Hairy cell leukemia (HCL) +
Common acute lymphoblastic leukemia (CALL) +
Pre-B acute lymphoblastic leukemia (pre-B-ALL) +
NULL-acute lymphoblastic leukemia (NULL-ALL) +
T common lymphocytic leukemia (T-CLL) -
Immunogen
Raji cells
Zastosowanie
Research Category
Inflammation & Immunology
Inflammation & Immunology
Research Sub Category
Immunoglobulins & Immunology
Immunoglobulins & Immunology
This Anti-Human B cells CD19 Antibody, clone FMC63 is validated for use in FC, IF for the detection of CD19.
This antibody is useful for enumerating normal B lymphocytes and typing B cell malignancies by flow cytometry and immunofluorescence.
SUGGESTED USAGE DILUTION
Flow cytometry and Indirect Immunofluorescence 1:25
Dilute with isotonic buffer. Use 50 μl of diluted antibody per 1 x 10E6 peripheral blood mononuclear cells (PBMC) in 100 μl buffer.
SUGGESTED USAGE DILUTION
Flow cytometry and Indirect Immunofluorescence 1:25
Dilute with isotonic buffer. Use 50 μl of diluted antibody per 1 x 10E6 peripheral blood mononuclear cells (PBMC) in 100 μl buffer.
Powiązanie
Replaces: CBL141
Postać fizyczna
Format: Purified
Purified from mouse ascitic fluid. The antibody is supplied in 25 mM Tris-HCl buffer, 0.4 M NaCl, pH 8.0, containing 0.2% bovine serum albumin and 0.1% sodium azide. The characteristics of each lot are tested by electrophoresis and flow cytometry.
Przechowywanie i stabilność
Store at 2 to 8°C, for up to 6 months. For prolonged periods, store below -20°C in undiluted aliquots. AVOID REPEATED FREEZE/THAW CYCLES.
WARNING: The monoclonal reagent solution contains 0.1% sodium azide as a preservative. Due to potential hazards arising from the build up of this material in pipes, spent reagent should be disposed of with liberal volumes of water.
WARNING: The monoclonal reagent solution contains 0.1% sodium azide as a preservative. Due to potential hazards arising from the build up of this material in pipes, spent reagent should be disposed of with liberal volumes of water.
Inne uwagi
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Informacje prawne
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Oświadczenie o zrzeczeniu się odpowiedzialności
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Narzędzie selektora produktów.
Kod klasy składowania
12 - Non Combustible Liquids
Klasa zagrożenia wodnego (WGK)
WGK 2
Temperatura zapłonu (°F)
Not applicable
Temperatura zapłonu (°C)
Not applicable
Certyfikaty analizy (CoA)
Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.
Masz już ten produkt?
Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.
Ye Lin et al.
Frontiers in neurology, 13, 808322-808322 (2022-03-18)
Myasthenia gravis (MG) is an autoimmune disease mediated by B cells secreting autoantibodies. Regulatory B (Breg) cells confirmed to have an immunosuppressive function play an important role in many autoimmune diseases. However, what about the changes in Breg cells in
Christine Ambrose et al.
PloS one, 16(3), e0247701-e0247701 (2021-03-19)
Successful CAR T cell therapy for the treatment of solid tumors requires exemplary CAR T cell expansion, persistence and fitness, and the ability to target tumor antigens safely. Here we address this constellation of critical attributes for successful cellular therapy
Fabiana Zappala et al.
Science advances, 8(18), eabn4613-eabn4613 (2022-05-07)
Extensive antibody engineering and cloning is typically required to generate new bispecific antibodies. Made-to-order genes, advanced expression systems, and high-efficiency cloning can simplify and accelerate this process, but it still can take months before a functional product is realized. We
Xing Du et al.
Cancer research, 68(15), 6300-6305 (2008-08-05)
B-cell malignancies routinely express surface antigens CD19 and CD22. Immunotoxins against both antigens have been evaluated, and the immunotoxins targeting CD22 are more active. To understand this disparity in cytotoxicity and guide the screening of therapeutic targets, we compared two
Stephanie N Shishido et al.
Journal for immunotherapy of cancer, 12(2) (2024-02-14)
Chimeric antigen receptor (CAR)-T cells are approved for use in the treatment of hematological malignancies. Axicabtagene ciloleucel (YESCARTA) and brexucabtagene autoleucel (TECARTUS) genetically modified autologous T cells expressing an anti-CD19 scFv based on the FMC63 clone have shown impressive response
Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.
Skontaktuj się z zespołem ds. pomocy technicznej